MGMT and neoplasm: Furthermore, 11 studies, including 464 patients with intestinal gastric cancer and 416 patients with diffuse gastric cancer, evaluated the association between MGMT methylation and tumor type; 10 studies including 221 stage 1–2 patients and 469 stage 3–4 patients evaluated the association between MGMT methylation and tumor stage; 9 studies assessed the correlation between MGMT promoter methylation and age status (more than or equal to 60 years: 387 GC patients, less than or equal to 60 years: 315 GC patients); and 3 studies involving 139 H.